Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Translate Bio
Thumbnail
October 20, 2021

Boehringer takes a different approach in cystic fibrosis gene therapy

Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.

Thumbnail
September 08, 2021

Sanofi makes another bolt-on with Kadmon

The “left field but logical” buy sees Sanofi gaining a graft-versus-host disease therapy to add to its transplant offering.

Article image
Vantage logo
August 03, 2021

Sanofi Translates its mRNA interest into big bucks

Sanofi’s $3.2bn move for Translate Bio leaves Arcturus as one of the few affordable independent mRNA players.

Article image
Vantage logo
July 08, 2021

Why Glaxo should buy Biohaven

And four other potential targets that could make sense for the beleaguered group.

Article image
Vantage logo
June 29, 2021

Better late than never for Sanofi mRNA vaccine push

Article image
Vantage logo
April 10, 2021

AACR 2021 – still awaiting validation, Sanofi keeps on buying

The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.

Article image
Vantage logo
March 18, 2021

Translate’s investment case shifts fully to Covid-19

The company’s lead cystic fibrosis asset fails, shifting the focus to the Sanofi-partnered Covid-19 vaccine.

Article image
Vantage logo
October 14, 2020

Ionis joins the inhaled cystic fibrosis therapy race

Ionis’s inhaled antisense candidate shows promising signs, with Arrowhead and Translate Bio also in the running.

Article image
Vantage logo
September 03, 2020

Sanofi and Glaxo join the Covid-19 vaccine chase

Article image
Vantage logo
August 21, 2020

The next triggers in Covid-19 vaccine development

Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.

Article image
Vantage logo
August 12, 2020

Moderna shows the value of bulk-buying

The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up